checkAd
    Startseite > Aktien > Evolus > Nachrichten
    Evolus Aktie
    12,500
     
    EUR
    +0,40 %
    +0,050 EUR
    Letzter Kurs 19:51:03 Lang & Schwarz
    12,400
     
    EUR
    813 STK
    Geldkurs 19:51:03
    12,600
     
    EUR
    813 STK
    Briefkurs 19:51:03
    ISIN: US30052C1071 · WKN: A2JDYX · USA

    Neueste Nachrichten

    Evolus to Report First Quarter Financial Results on May 7, 2024
    23.04.24 · Business Wire (engl.) · Evolus
    Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau
    17.04.24 · Business Wire (engl.) · Evolus
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    12.04.24 · Business Wire (engl.) · Evolus
    Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    26.03.24 · Business Wire (engl.) · Evolus
    Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
    11.03.24 · Business Wire (engl.) · Evolus
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    08.03.24 · Business Wire (engl.) · Evolus
    Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
    07.03.24 · Business Wire (engl.) · Evolus
    Evolus Announces Results from European Head-to-Head Filler Trial
    01.03.24 · Business Wire (engl.) · Evolus
    Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
    27.02.24 · Business Wire (engl.) · Evolus
    Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
    22.02.24 · Business Wire (engl.) · Evolus
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    09.02.24 · Business Wire (engl.) · Evolus
    Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
    16.01.24 · Business Wire (engl.) · Evolus